Wechselwirkungen · Darunavir Krka
Darunavir Krka 400 mg film-coated tablets Darunavir Krka 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 22
HOS-225742 · Präparat HOS-217490
Midazolam (oral) Boosted darunavir with triazolam or Triazolam oral midazolam is contraindicated (see section 4.3). TREATMENT FOR PREMATURE EJACULATION Dapoxetine Not studied. Co-administration of boosted darunavir with dapoxetine is contraindicated. UROLOGICAL DRUGS Fesoterodine Not studied. Use with caution. Monitor for Solifenacin fesoterodine or solifenacin adverse reactions, dose reduction of fesoterodine or solifenacin may be necessary. # Studies have been performed at lower than recommended doses of darunavir or with a different dosing regimen (see section 4.2 Posology). † The efficacy and safety of the use of darunavir with 100 mg ritonavir and any other HIV PI (e.g. (fos)amprenavir and tipranavir) has not been established in HIV patients. According to current treatment guidelines, dual therapy with protease inhibitors is generally not recommended. ‡ Study was conducted with tenofovir disoproxil fumarate 300 mg once daily.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): solifenacin (HOS-116433) protease (HOS-085623) amprenavir (HOS-086183) fesoterodine (HOS-116432) tenofovir disoproxil fumarate (HOS-110471) ritonavir (HOS-084521) triazolam (HOS-086168) tipranavir (HOS-086184) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-01-28T02:00:00Z · SHA-256 42a250050090ba77cfec6bb0ff0fc9dbbb4e1a422df7d45e8efc6fc459616a05 · Passage a113de26c97bc735407c10a633929fed0820a116b819207060898b2ee86fdd7c · Zeichen 71469–73405 im Abschnitt